MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better

Moderna, Inc. (MRNA) is on track to become September’s second-best performer in the S&P 500, but five smaller stocks have delivered even larger gains this month, driven by developments ranging from an impending ALS trial readout to a cancer-test regulatory review, and, in one case, a Zcash strategy…